FDA Deputy Commissioner for Human Foods Kyle Diamantas spoke directly at a Natural Products Association fireside chat this week, stating that the dietary supplement industry has grown in size, scope, and science far beyond what DSHEA’s 1994 framework anticipated, and that the agency’s regulatory posture must adapt accordingly. Diamantas emphasized that modernization priorities include addressing bad actors in the marketplace, streamlining new dietary ingredient notifications, and reforming disclosure requirements that impose cost without delivering meaningful consumer protection. He called the MAHA agenda a once-in-a-generation opportunity to align supplement oversight with current public health science.

SupplySide Supplement Journal published an analysis confirming that the Make America Healthy Again initiative is creating direct political momentum for FDA to revisit DSHEA-era regulatory assumptions, with Diamantas describing MAHA as providing the agency a renewed mandate to act where it previously lacked urgency. The report highlights FDA’s stated goal of developing cleaner pathways for responsible manufacturers while closing gaps that allow adulterated or misbranded products to reach consumers. Importantly, Diamantas indicated the agency wants a supplement industry that “succeeds,” framing modernization as an industry opportunity rather than a punitive overhaul.

Following FDA’s March 27 public meeting, industry stakeholders continued debating whether the definition of “dietary substance” under DSHEA should be broadened to encompass novel ingredients produced through precision fermentation, cell culture technology, and recombinant production, with consumer advocates urging caution and manufacturers calling for regulatory clarity. The public comment period under docket FDA-2026-N-2047 closes April 27, meaning the industry has less than two weeks to formally weigh in on definitions that could reshape the supplement market for the next decade. Major business news from the week included Herbalife’s acquisition of personalized supplement platform Bioniq for up to $150 million, signaling continued investor confidence in the premium supplement sector.

The Consumer Product Safety Commission announced that Vitaquest International LLC of West Caldwell, New Jersey is recalling approximately 356,140 units of iron-containing dietary supplements across 11 brands, including products sold at Ulta Beauty, The Vitamin Shoppe, Erewhon, and Amazon, due to packaging that fails to meet the mandatory child-resistant standard required by the federal Poison Prevention Packaging Act. Children who access and swallow the contents face a risk of serious injury or death from iron poisoning, and the recall underscores the ongoing challenge of GMP compliance in contract manufacturing under DSHEA. Affected consumers should immediately store the supplements out of reach of children and contact Vitaquest International at 844-298-4545 for a free replacement cap or storage pouch.

Blueroot Health expanded its voluntary recall of Vital Nutrients Aller-C dietary supplements to include all product manufactured under lot 25E04, after routine internal testing detected undeclared egg, hazelnut, and soy allergens that were absent from the product label. The expanded recall affects white plastic bottles of either 100 or 200 capsules with lot numbers 25E04, 25E04-A, or 25E04-B and an expiration date of May 2027, sold through VitalNutrients.co and other online retailers between September 2025 and March 2026. The incident highlights a recurring gap in DSHEA’s pre-market review structure: allergen contamination is typically discovered only through post-market testing, leaving consumers exposed in the interim.

A multistate Salmonella outbreak linked to moringa leaf powder dietary supplements has grown to 68 confirmed cases across multiple states, with FDA and CDC investigators urging consumers to immediately discard recalled Why Not Natural and Live it Up brand products. The strain involved has shown extensive drug resistance, complicating treatment options and raising serious public health concerns that reach beyond a typical supplement contamination event. The ongoing outbreak directly demonstrates the enforcement limitations inherent in DSHEA’s post-market safety model, reinforcing calls from both regulators and consumer advocates for stronger pre-market contamination controls.

China-sourced botanical ingredients, including ashwagandha, ginseng, elderberry, turmeric, and boswellia, are now subject to combined tariff rates approaching 145 percent, with no exemptions currently in place for herb and plant extract categories, according to SupplySide Supplement Journal. American Herbal Products Association President Graham Rigby warned that many China-sourced ingredients are “difficult or impossible to replace domestically,” meaning tariff costs will ultimately be passed to consumers or force product reformulation. The supplement industry, which depends on China for approximately 80 percent of botanical raw material, faces a supply chain disruption unlike any seen since the passage of DSHEA itself.

A detailed analysis from Nutraceuticals World identifies herbs and botanicals as the dietary supplement ingredient category facing the most severe tariff exposure, with suppliers reporting sudden procurement disruptions that threaten product availability across the natural health market. While vitamins, amino acids, and select minerals were included in tariff exemption lists, the botanical sector, representing a substantial share of DSHEA-covered products sold in the United States, received no relief. Industry observers warn that shifting sourcing relationships to non-Chinese suppliers is a multi-year process, meaning the impact on supplement pricing and access could persist well into 2027 and beyond.

This week’s global industry roundup from NutraIngredients highlighted Holland & Barrett’s significant capital commitment to expanding its premium supplement portfolio, reflecting sustained consumer demand for science-backed, transparent products even as economic headwinds from tariffs create pressure across the supply chain. The report also tracked FDA’s continued MAHA implementation signals and the European debut of Solnul, a resistant potato starch ingredient, which analysts suggest may foreshadow U.S. regulatory filings given the ingredient’s established safety profile. Together, these developments point to a global supplement market in active evolution, where regulatory frameworks like DSHEA face simultaneous pressure to modernize and to demonstrate robust safety oversight.

The FDA’s public comment period on the scope of dietary supplement ingredients closes April 27, 2026. This is one of the most consequential comment opportunities since DSHEA was enacted, covering whether novel ingredients produced via precision fermentation and cell culture may be marketed as dietary supplements. Your comment, submitted under docket FDA-2026-N-2047, directly shapes the future of what DSHEA can protect.

Submit Your Comment

You are receiving this because you subscribed to the DSHEA Weekly Digest.
© 2026 DSHEA Preservation Alliance. All rights reserved.
Powered by PICXM